Industry News
Alcon to Acquire LENSAR in Strategic Expansion of Cataract Surgery Portfolio
Alcon has announced a definitive agreement to acquire LENSAR, Inc. (NASDAQ: LNSR), a medical technology company specialising in advanced laser solutions for cataract treatment. The deal, valued at up to USD 430 million, aims to strengthen Alcon’s portfolio in femtosecond laser-assisted cataract surgery (FLACS) and enhance the global adoption of innovative cataract treatment solutions.
Under the terms of the acquisition, Alcon will purchase LENSAR’s outstanding shares at USD 14.00 per share in cash, with an additional contingent value right (CVR) of up to USD 2.75 per share, contingent upon LENSAR products reaching 614,000 cumulative procedures between January 2026 and December 2027.
“We are excited for the opportunity to bring LENSAR’s unique next-generation technologies and intellectual property into our innovative, market-leading equipment portfolio,” said David Endicott, Chief Executive Officer of Alcon. “By leveraging our global footprint, we have the opportunity to deliver the benefits of advanced femtosecond laser technology to many more surgeons around the world and continue to improve efficiency in cataract surgery.”
LENSAR’s ALLY Robotic Cataract Laser Treatment System™ and proprietary Streamline® software will be incorporated into Alcon’s surgical portfolio, offering enhanced precision, efficiency, and automation for cataract procedures. The ALLY system, designed for both in-office surgical suites and traditional operating theatres, utilises AI-powered imaging and dual-modality laser technology to improve procedural outcomes.
“Our focus has been on providing surgeons with breakthrough laser technology in cataract surgery for today and tomorrow,” said Nick Curtis, Chief Executive Officer of LENSAR. “Thanks to the continued passion and commitment of LENSAR associates, customers and our investors, we are excited about the potential Alcon has to advance the industry in next-generation laser technology for refractive cataract surgery, furthering our and their mission to meet the needs of both surgeons and their cataract patients.”
The global cataract surgery market continues to grow, with over 32 million procedures performed annually. Femtosecond laser-assisted cataract surgery provides surgeons with advanced tools to improve precision and patient outcomes while streamlining workflow efficiency. The acquisition aligns with Alcon’s broader strategy to expand its footprint in surgical innovation and reinforce its leadership in ophthalmic solutions.
The transaction is expected to close in mid-to-late 2025, subject to customary regulatory approvals and shareholder consent. Financial advisory services for the deal are being provided by Lazard for Alcon and Wells Fargo for LENSAR, with Norton Rose Fulbright and Latham & Watkins LLP serving as legal advisors.
This acquisition signals Alcon’s continued investment in high-growth, technology-driven segments of the ophthalmic industry, reinforcing its commitment to advancing vision care worldwide.
